Nothing Special   »   [go: up one dir, main page]

HK1131608A1 - Pyridinone compounds - Google Patents

Pyridinone compounds

Info

Publication number
HK1131608A1
HK1131608A1 HK09110170.2A HK09110170A HK1131608A1 HK 1131608 A1 HK1131608 A1 HK 1131608A1 HK 09110170 A HK09110170 A HK 09110170A HK 1131608 A1 HK1131608 A1 HK 1131608A1
Authority
HK
Hong Kong
Prior art keywords
pyridinone compounds
compound
directed
pyridinone
cancer
Prior art date
Application number
HK09110170.2A
Other languages
English (en)
Inventor
Robert M Borzilleri
Gretchen M Schroeder
Zhen-Wei Cai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1131608A1 publication Critical patent/HK1131608A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
HK09110170.2A 2006-11-08 2009-11-02 Pyridinone compounds HK1131608A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85754006P 2006-11-08 2006-11-08
PCT/US2007/084047 WO2008058229A1 (en) 2006-11-08 2007-11-08 Pyridinone compounds

Publications (1)

Publication Number Publication Date
HK1131608A1 true HK1131608A1 (en) 2010-01-29

Family

ID=39048786

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09110170.2A HK1131608A1 (en) 2006-11-08 2009-11-02 Pyridinone compounds

Country Status (21)

Country Link
US (2) US7851489B2 (xx)
EP (1) EP2089364B1 (xx)
JP (1) JP5276005B2 (xx)
KR (1) KR101390076B1 (xx)
CN (1) CN101535264B (xx)
AR (1) AR063628A1 (xx)
AU (1) AU2007317296B2 (xx)
CA (1) CA2669266C (xx)
CL (1) CL2007003226A1 (xx)
DK (1) DK2089364T3 (xx)
ES (1) ES2424851T3 (xx)
HK (1) HK1131608A1 (xx)
HR (1) HRP20130626T1 (xx)
MX (1) MX2009004699A (xx)
NO (1) NO342395B1 (xx)
PE (1) PE20081490A1 (xx)
PL (1) PL2089364T3 (xx)
PT (1) PT2089364E (xx)
SI (1) SI2089364T1 (xx)
TW (1) TWI409259B (xx)
WO (1) WO2008058229A1 (xx)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101608096B1 (ko) 2008-01-23 2016-03-31 브리스톨-마이어스 스큅 컴퍼니 ４-피리디논 화합물 및 암을 위한 그의 용도
MX2010012848A (es) 2008-06-03 2011-03-01 Intermune Inc Compuestos y metodos para tratar trastornos inflamatorios y fibroticos.
WO2011139891A1 (en) 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
SI2563763T1 (sl) * 2010-04-30 2015-03-31 Bristol-Myers Squibb Company Farmacevtski sestavki, ki obsegajo N-(4-(2-amino-3-kloropiridin-4-iloksi)-3-fluorofenil)-4-etoksi-L-(4- fluorofenil)-2-okso-1,2-dihidropiridin-3-karboksamid
CN102241625B (zh) * 2010-05-13 2014-10-29 中南大学 1-(取代芳基)-5-((取代芳胺基)甲基)吡啶-2(1h)酮化合物、制备方法及其用途
CN102070518B (zh) * 2011-01-24 2012-05-02 江苏先声药物研究有限公司 取代吡啶及氮杂吲哚衍生物的合成
LT2718270T (lt) 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
JP2015507606A (ja) * 2011-11-22 2015-03-12 デシフェラ ファーマシューティカルズ，エルエルシー 抗癌および抗増殖作用を示すピリドンアミドおよび類似体
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
CA2876246C (en) 2012-07-28 2019-05-07 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3126362B1 (en) 2014-04-02 2022-01-12 Intermune, Inc. Anti-fibrotic pyridinones
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
EP4141002A1 (en) 2015-11-19 2023-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170174679A1 (en) 2015-12-22 2017-06-22 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3472167T2 (ro) 2016-06-20 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MA45669A (fr) * 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3044366A1 (en) * 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119266A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Benzooxazole derivatives as immunomodulators
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
CN108623568B (zh) * 2017-03-21 2022-04-19 南京汇诚制药有限公司 9,10二氢菲类丙型肝炎病毒抑制剂的盐型及其制备
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2019083455A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS PRESENTING HER1, HER2 AND / OR HER3-ACTIVATED HERC-RECEPTOR CANCER CELLS
WO2019083458A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR THE TREATMENT OF CANCER TO REDUCE HYPOXIA
WO2019083457A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER IN A PATIENT IDENTIFIED AS MUTATION OF THE BETA-CATENIN PATHWAY
WO2019083456A1 (en) 2017-10-25 2019-05-02 Aslan Pharmaceuticals Pte Ltd VARLITINIB FOR USE IN THE TREATMENT OF CANCER FOR NORMALIZING ANGIOGENESIS IN A CANCER MASS
EP3719012B1 (en) * 2017-11-24 2024-03-06 Medshine Discovery Inc. N-[4-[(2-amino-4-pyridinyl)oxy]-3-fluorophenyl]-3-(4-fluorophenyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinecarboxamide derivatives as c-met/axl inhibitors for the treatment of tumors
KR102221689B1 (ko) 2018-03-08 2021-03-02 웰마커바이오 주식회사 티에노피리딘 유도체 및 이를 포함하는 약학적 조성물
EP3790877B1 (en) 2018-05-11 2023-03-01 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
JP2022504201A (ja) 2018-10-09 2022-01-13 アスラン ファーマシューティカルズ ピーティーイー リミテッド バリチニブのマロン酸塩
EP3867229A4 (en) * 2018-10-19 2022-07-27 The University Of British Columbia TOPOISOMERASE II CATALYTIC INHIBITOR COMPOUND THERAPEUTIC AGENTS FOR CANCER TREATMENT, METHODS AND USES
EP3911320A4 (en) * 2019-01-15 2022-11-30 The Translational Genomics Research Institute PHOSPHONATE CONJUGATES AND USES THEREOF
CN114206883A (zh) 2019-08-02 2022-03-18 伟迈可生物有限公司 氧代吡啶稠环衍生物及包含该衍生物的药物组合物
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
US20230172914A1 (en) 2019-09-06 2023-06-08 Wellmarker Bio Co., Ltd. Biomarker-based therapeutic composition
JP2023500395A (ja) 2019-11-11 2023-01-05 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩及び結晶形態
WO2021158071A1 (ko) 2020-02-06 2021-08-12 웰마커바이오 주식회사 Kras 돌연변이와 관련된 암의 예방 또는 치료용 약학 조성물
KR20210111711A (ko) 2020-03-03 2021-09-13 웰마커바이오 주식회사 Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물
CN115916210A (zh) 2020-05-18 2023-04-04 伟迈可生物有限公司 用于预防或治疗与ron突变相关的小细胞肺癌的药物组合物及其使用方法
US20230242521A1 (en) 2020-05-18 2023-08-03 Wellmarker Bio Co., Ltd. Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same
EP4154891A4 (en) 2020-05-18 2023-12-06 Wellmarker Bio Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF RON MUTATION ASSOCIATED NON-SMALL CELL LUNG CANCER AND METHOD FOR THE USE THEREOF
CN116670114A (zh) 2020-11-06 2023-08-29 因赛特公司 用于制备pd-1/pd-l1抑制剂以及其盐和结晶形式的方法
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
JP2024505258A (ja) * 2021-02-02 2024-02-05 エルジー・ケム・リミテッド タンパク質キナーゼ阻害剤としての新規な化合物
US20240293386A1 (en) * 2021-06-22 2024-09-05 Lg Chem, Ltd. Novel compound as protein kinase inhibitor
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof
KR20240101434A (ko) * 2022-12-23 2024-07-02 주식회사 엘지화학 Ron 억제제로서 신규한 화합물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430885A3 (en) 1989-12-01 1991-11-06 Ciba-Geigy Ag Anthelmintical compounds
WO1997017329A1 (fr) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
AU4692399A (en) 1998-06-17 2000-01-05 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6355660B1 (en) 1999-07-20 2002-03-12 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
CA2374995C (en) 1999-07-20 2010-12-07 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
SK3822002A3 (en) 1999-09-21 2002-10-08 Astrazeneca Ab Quinazoline derivatives, process for the preparation thereof and their use
FR2812633A1 (fr) 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
SE0102384D0 (sv) 2001-07-03 2001-07-03 Pharmacia Ab New compounds
JP2005510564A (ja) 2001-11-28 2005-04-21 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP2005263787A (ja) 2004-02-17 2005-09-29 Ishihara Sangyo Kaisha Ltd アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
CA2564355C (en) 2004-05-07 2012-07-03 Amgen Inc. Protein kinase modulators and method of use
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
CN101535264B (zh) 2012-11-28
WO2008058229A1 (en) 2008-05-15
EP2089364B1 (en) 2013-06-12
TW200829564A (en) 2008-07-16
AU2007317296A1 (en) 2008-05-15
US20080114033A1 (en) 2008-05-15
US20110052583A1 (en) 2011-03-03
CA2669266A1 (en) 2008-05-15
US7851489B2 (en) 2010-12-14
PE20081490A1 (es) 2008-10-30
JP5276005B2 (ja) 2013-08-28
ES2424851T3 (es) 2013-10-09
CN101535264A (zh) 2009-09-16
PT2089364E (pt) 2013-08-26
AR063628A1 (es) 2009-02-04
EP2089364A1 (en) 2009-08-19
CL2007003226A1 (es) 2008-02-08
HRP20130626T1 (xx) 2013-08-31
US8536200B2 (en) 2013-09-17
KR20090096423A (ko) 2009-09-10
JP2010509362A (ja) 2010-03-25
KR101390076B1 (ko) 2014-04-29
AU2007317296B2 (en) 2012-07-05
SI2089364T1 (sl) 2013-10-30
CA2669266C (en) 2014-04-29
NO20091605L (no) 2009-05-27
TWI409259B (zh) 2013-09-21
NO342395B1 (no) 2018-05-14
DK2089364T3 (da) 2013-09-02
PL2089364T3 (pl) 2013-11-29
MX2009004699A (es) 2009-05-15

Similar Documents

Publication Publication Date Title
HK1131608A1 (en) Pyridinone compounds
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2011009796A (es) Inhibidores de la cinasa pi3.
WO2009155121A3 (en) Inhibitors of pi3 kinase
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
GEP20135925B (en) Inhibitors of hedgehog pathway
EP3483143A8 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
GEP20166484B (en) Protein kinase inhibitors
NZ577916A (en) Cyclopamine analogs
JO2848B1 (en) Organic compounds
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
GEP20156285B (en) Compounds and compositions as trk inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
AU2009282962A8 (en) Compounds as kinase inhibitors